Skip to main content

Advertisement

SpringerLink
Log in

Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

We used 18F-FDG PET to evaluate the FDG uptake in patients with aggressive fibromatosis (AF, also known as desmoid tumours) undergoing therapy with imatinib (imatinib mesylate, Glivec).

Methods

The pilot study included nine patients with progressive AF receiving oral treatment with imatinib at a daily dose of 800 mg. Patients were examined using PET prior to the start of therapy and during imatinib treatment. Restaging according to the Response Evaluation Criteria in Solid Tumors (RECIST) was performed in parallel using CT and/or MRI and served as reference.

Results

The clinical outcomes in nine evaluable patients were as follows: seven patients with stable disease, and two patients with progressive disease. A 27% decrease in the median average standardized uptake value (SUV) of the sequential PET examinations was demonstrated in all evaluable patients with three patients (33%) showing a decrease in SUV of more than 40% (48%, 52% and 54%, respectively); no patient showed a substantial increase in SUV.

Conclusion

To our knowledge, this is the first series of AF patients undergoing treatment with imatinib and monitored using sequential PET imaging, that allows detection of SUV changes after imatinib induction, thus helping to decide whether treatment should be continued or not.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Biermann JS. Desmoid tumors. Curr Treat Options Oncol 2000;1:262–6.

    Article  CAS  PubMed  Google Scholar 

  2. Micke O, Seegenschmiedt MH. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national patterns of care study. Int J Radiat Oncol Biol Phys 2005;61:882–91.

    PubMed  Google Scholar 

  3. Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P, et al. Hereditary colorectal tumor registry. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003;21:1698–707.

    Article  CAS  PubMed  Google Scholar 

  4. Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg 1996;83:1494–504.

    Article  CAS  PubMed  Google Scholar 

  5. Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003;14:181–90.

    Article  CAS  PubMed  Google Scholar 

  6. Pignatti G, Barbanti-Bròdano G, Ferrari D, Gherlinzoni F, Bertoni F, Bacchini P, et al. Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop Relat Res 2000;375:207–13.

    Article  PubMed  Google Scholar 

  7. Knudsen AL, Bülow S. Desmoid tumour in familial adenomatous polyposis. A review of literature. Fam Cancer 2001;1:111–9.

    Article  CAS  PubMed  Google Scholar 

  8. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY, ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 Suppl 2:ii89–93.

    Article  PubMed  Google Scholar 

  9. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–6.

    Article  CAS  PubMed  Google Scholar 

  10. qqHeinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925–32.

    CAS  PubMed  Google Scholar 

  11. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172–87.

    Article  CAS  PubMed  Google Scholar 

  12. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.

    Article  PubMed  Google Scholar 

  13. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80.

    Article  CAS  PubMed  Google Scholar 

  14. qqHeinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342–9.

    Article  CAS  PubMed  Google Scholar 

  15. qqHeinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708–10.

    Article  CAS  PubMed  Google Scholar 

  16. Mace J, Sybill BJ, Sondak V, McGinn C, Hayes C, Thomas D, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373–9.

    Article  CAS  PubMed  Google Scholar 

  17. Leithner A, Gapp M, Radl R, Pascher A, Krippl P, Leithner K, et al. Immunohistochemical analysis of desmoid tumours. J Clin Pathol 2005;58:1152–6.

    Article  CAS  PubMed  Google Scholar 

  18. qqHeinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumour). J Clin Oncol 2006;24:1195–203.

    Article  CAS  PubMed  Google Scholar 

  19. Penel N, Le Cesne A, Bui B, Tubiana-Hulin M, Guillemet C, Cupissol D, et al. Imatinib for the treatment of aggressive fibromatosis (desmoid tumors) failing local treatment. A phase II trial of the French Sarcoma Group. ASCO Meeting Abstracts 2006, 24:9516.

    Google Scholar 

  20. Dufresne A, Penel N, Salas S, Le Cesne A, Perol D, Bui B, et al. Updated outcome with long-term follow-up of imatinib for the treatment of progressive or recurrent aggressive fibromatosis (desmoid tumor): A FNCLCC/French Sarcoma Group phase II trial. ASCO Meeting Abstracts 2009, 27:10518.

    Google Scholar 

  21. Chugh R, Maki RG, Thomas DG, Reinke D, Wathen JK, Patel S, et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. ASCO Meeting Abstracts 2006, 24:9515.

    Google Scholar 

  22. Wendtner CM, Abdel-Rahman S, Krych M, Baumert J, Lindner LH, Baur A, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 2002;20:3156–64.

    Article  CAS  PubMed  Google Scholar 

  23. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623–48.

    CAS  PubMed  Google Scholar 

  24. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig G, Sarkar MR, et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumors: is a non-invasive determination of biological activity possible? Eur J Nucl Med Mol Imaging 1999;26:599–605.

    Article  CAS  Google Scholar 

  25. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 1998;39:250–4.

    CAS  PubMed  Google Scholar 

  26. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339–48.

    Article  PubMed  Google Scholar 

  27. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol 2006;18:369–73.

    Article  PubMed  Google Scholar 

  28. Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984;33:37–42.

    Article  CAS  PubMed  Google Scholar 

  29. Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, et al. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005;241:286–94.

    Article  PubMed  Google Scholar 

  30. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519–27.

    PubMed  Google Scholar 

  31. Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med 1997;38:1818–23.

    CAS  PubMed  Google Scholar 

  32. Cheng EY, Froelich JW, Manivel JC, Weigel J, Skubitz KM. Correlation of FDG PET-CT with histologic response after neoadjuvant chemotherapy for soft tissue sarcomas. ASCO Meeting Abstracts 2009, 27:10583.

    Google Scholar 

  33. Kasper B, Dietrich S, Dimitrakopoulou-Strauss A, Strauss LG, Haberkorn U, Ho AD, et al. Early prediction of therapy outcome in patients with high risk soft tissue sarcoma using positron emission tomography. Onkologie 2008;31:107–12.

    Article  PubMed  Google Scholar 

  34. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004;25:433–8.

    Article  CAS  PubMed  Google Scholar 

  35. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S–50S.

    Article  CAS  PubMed  Google Scholar 

  36. Ramos-Font C, Santiago Chinchilla A, Rebollo Aguirre AC, Rodríguez Fernández A, Medina Benítez A, Llamas Elvira JM. Desmoid tumor of the thoraco-abdominal wall characterized with 18F-fluorodeoxyglucose PET/CT scan. Correlation with magnetic resonance and bone scintigraphy. Review of the literature. Rev Esp Med Nucl 2009;28:70–3.

    Article  CAS  PubMed  Google Scholar 

  37. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Schmitt T, Haberkorn U, et al. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. Eur J Nucl Med Mol Imaging 2010. doi:10.1007/s00259-010-1435-z.

  38. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Mechtersheimer G, Schmitt T, et al. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med 2010;51:551–8.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Sarcoma Unit, ITM - Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany

    Bernd Kasper & Peter Hohenberger

  2. Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany

    Antonia Dimitrakopoulou-Strauss & Ludwig G. Strauss

Authors
  1. Bernd Kasper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonia Dimitrakopoulou-Strauss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ludwig G. Strauss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Hohenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernd Kasper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kasper, B., Dimitrakopoulou-Strauss, A., Strauss, L.G. et al. Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib. Eur J Nucl Med Mol Imaging 37, 1876–1882 (2010). https://doi.org/10.1007/s00259-010-1498-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-010-1498-x

Keywords

Search

Navigation